Clinical trials · Massachusetts
Cancer clinical trials in Massachusetts
We’re tracking 756 recruiting cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Boston, MassachusettsAges 18–130 - NCT06427954Recruiting
Mobile app study for people with advanced lung cancer
This study tests a mobile app (called THRIVE) to help people with advanced lung cancer manage their health and well-being. You'll use the app on your phone to track symptoms and get support, which may help you feel better and stay more in control.
Boston, MassachusettsAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Boston, MassachusettsAges 12 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Boston, MassachusettsAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Boston, MassachusettsAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Boston, MassachusettsAges 18 years+ - NCT06486454Recruiting
Liver tumor treatment with sound waves
This trial tests a new device that uses sound waves to destroy liver tumors without cutting or needles. It may be an option if you have a liver tumor that can be partly or fully targeted by this technique.
Boston, MassachusettsAges 22 years+ - NCT06517901Recruiting
Comparing two MRI-guided biopsy methods for prostate cancer
This trial compares two ways to use MRI images during a prostate biopsy to see which finds cancer better. It looks at 'fusion' biopsy (where a computer combines MRI with live ultrasound) versus 'cognitive' biopsy (where the doctor mentally matches the MRI to the ultrasound).
Burlington, MassachusettsAges 18 years+ - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06538636Recruiting
Improving lung cancer screening for Veterans
This study is testing a new way to find Veterans who might benefit from yearly lung cancer screening. It uses a computer model to estimate your personal benefit, even if you don't fit the usual screening guidelines.
Boston, MassachusettsAges 50–80 - NCT06551220Recruiting
T-DXd for advanced breast cancer with various HER2 levels
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
Boston, MassachusettsAges 18–80 - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Boston, MassachusettsAges 18 years+ - NCT06579417Recruiting
Testing a faster MRI for prostate cancer detection
This trial is testing a new, faster type of MRI scan (called biparametric MRI) to see if it can detect prostate cancer as well as the standard scan. It may help you avoid a longer scan and possibly reduce the need for contrast dye.
Boston, MassachusettsAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Boston, MassachusettsAges 18 years+ - NCT06643884RecruitingPhase 2
Study of eye injection for cancer that spread to the choroid
This trial tests a new way to deliver treatment directly into the eye (through a thin space near the choroid) for people whose cancer has spread to the eye. It aims to see if this targeted approach can safely shrink the eye tumors.
Boston, MassachusettsAges 18 years+ - NCT06651580Recruiting
Gene study for kids with pancreas problems
This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.
Boston, MassachusettsAges Up to 17 years - NCT06686394RecruitingPhase 1/Phase 2
New drug combo for HER2+ breast cancer that has spread
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
Boston, MassachusettsAges 18 years+ - NCT06780137RecruitingPhase 1/Phase 2
Gocatamig plus ifinatamab deruxtecan for advanced small cell lung cancer
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Boston, MassachusettsAges 1–21 - NCT07226427RecruitingPhase 1
Study of MEN2501 for platinum-resistant ovarian cancer
This trial tests a new drug called MEN2501 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it is safe and if it can help shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Boston, MassachusettsAges 18 years+ - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Burlington, MassachusettsAges 18 years+ - NCT06795529Recruiting
Palliative care support for metastatic breast cancer
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
Boston, MassachusettsAges 18 years+
Cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting cancer studies listed above.
- Dana-Farber Cancer Institute · 8 studies
- Massachusetts General Hospital · 8 studies
- Boston Medical Center · 2 studies
- Lahey Hospital and Medical Center · 2 studies
- Boston Children's Hospital
- Brigham and Women's Hospital
- Brigham and Women's-Mass General Health Care Center
- Dana-Farber Cancer Institute - Merrimack Valley
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 756 recruiting cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.